Skip to main content
VIVOZON PHARMACEUTICAL CO., LTD. logo

VIVOZON PHARMACEUTICAL CO., LTD. — Investor Relations & Filings

Ticker · 082800 ISIN · KR7082800004 KO Manufacturing
Open in API
Filings indexed 590 across all filing types
Latest filing 2026-01-08 Regulatory Filings
Country KR South Korea
Listing KO 082800

About VIVOZON PHARMACEUTICAL CO., LTD.

https://www.vivozon.com/

VIVOZON PHARMACEUTICAL CO., LTD. is a research and development company specializing in the discovery and commercialization of innovative drugs, with a primary focus on pain and central nervous system (CNS) diseases. The company utilizes a multi-target drug development platform to create new chemical entities that act on multiple targets to achieve synergistic efficacy. This approach integrates efficacy-based screening from the early stages of discovery to identify candidate substances with a high potential for successful clinical development. Its lead pipeline candidate is Opiranserin (VVZ-149), a first-in-class, non-narcotic injectable analgesic for post-operative pain management. The company is actively expanding its pipeline to address a broader range of unmet medical needs within the CNS field.

Recent filings

Filing Released Lang Actions
[기재정정]투자설명서
Regulatory Filings Classification · 95% confidence The document is a 'Registration Statement' (투자설명서) amendment filed by Vivozon Pharmaceutical. It details changes to the offering price (1차 발행가액 확정) for a rights offering (유상증자). In the context of Korean financial filings (DART), this is a formal regulatory filing related to capital raising. Since it is a detailed prospectus amendment rather than a simple announcement of a report, it falls under the 'Regulatory Filings' category as the most appropriate classification for this type of formal securities registration document.
2026-01-08 Korean
권리락 (유상증자)
Share Issue/Capital Change Classification · 95% confidence The document is a short announcement regarding a 'rights offering' (유상증자) and the resulting 'ex-rights' (권리락) date for Vivozon Pharmaceutical. It provides specific details on the stock code, reference price, and the reason for the corporate action. Since it announces a change in capital structure/share issuance rather than the full report or a general regulatory notice, it fits the 'Share Issue/Capital Change' category.
2026-01-08 Korean
투자설명서
Investor Presentation Classification · 98% confidence The document is a '투자설명서' (Investment Prospectus) for Vivozon Pharmaceutical. It contains detailed information regarding a capital raise (10,615,000 shares, 49.9 billion KRW), subscription periods, and comprehensive risk factors (business, industry, and company-specific risks). This document is a formal regulatory filing required for public offerings of securities in South Korea, which falls under the category of a Prospectus/Proxy Solicitation/Information Statement. Given the specific nature of the document as a formal investment prospectus for a capital increase, it is classified as a Proxy Solicitation & Information Statement (PSI).
2026-01-07 Korean
[기재정정]증권신고서(지분증권)
Regulatory Filings Classification · 95% confidence The document is a 'Securities Registration Statement' (증권신고서) amendment (정정신고) filed by Vivozon Pharmaceutical. It details specific amendments to the original registration statement, including updates to risk factors, business operations, and financial disclosures. This is a formal regulatory filing required for public offerings or capital changes, which falls under the 'Regulatory Filings' category as it is a specific legal document type not covered by the other specialized categories like 10-K or Earnings Release.
2026-01-06 Korean
[기재정정]주요사항보고서(유상증자결정)
Share Issue/Capital Change Classification · 100% confidence The document is a 'Major Matter Report' (주요사항보고서) regarding a 'Capital Increase Decision' (유상증자결정) and its subsequent amendment (정정신고). It details the issuance of new shares, subscription dates, pricing methods, and allocation procedures. This falls under the category of announcements regarding new share issues and capital structure changes, which is classified as 'SHA'.
2025-12-19 Korean
[기재정정]증권신고서(지분증권)
Regulatory Filings Classification · 95% confidence The document is a '증권신고서(지분증권) 정정신고' (Securities Registration Statement Amendment) for Vivozon Pharmaceutical. It details amendments to a previously filed registration statement, including updates to the offering schedule, risk factors, and business information. In the context of financial filings, a Securities Registration Statement (and its amendments) is a regulatory document filed with the financial authority (FSS/DART in Korea) to register securities for public offering. Since it does not fit into specific categories like '10-K' (Annual Report) or 'ER' (Earnings Release), and is a formal regulatory filing for a capital-raising event, it is classified as a Regulatory Filing.
2025-12-19 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.